Aspirin in ischemic cerebrovascular disease: How strong is the case for a different dosing regimen?

Stroke

Volumn 27, Issue 4, 1996, Pages 756-760

  Patrono, Carlo ^a   Roth, Gerald J ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

antiplatelet therapy; aspirin; stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID;

CEREBROVASCULAR DISEASE; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GOOD CLINICAL PRACTICE; HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE;

EID: 0029916612     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.4.756     Document Type: Review

References (36)

1. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330: 1287-1294.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 1971;231:232-235.
4. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073-3076.
5. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980; 17:317-327.
6. Patrignani P, Filabozzi P. Patrono C. Selective cumulative inhibition of thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
7. Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, Tack-Goldman K, Gay WA Jr. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800-805.
8. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davì G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177-1184.
9. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325: 1261-1266.
10. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis: fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989;250:154-161.
11. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation. 1992;85:1077-1082.
12. Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992;80: 2006-2011.
13. Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, mutagenesis and gene chromosomal assignment. FASEB J. 1991;5:2304-2312.
14. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72:2294-2298.
15. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol. 1991;68: 11B-15B.
16. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
17. Koudstaal PJ, Ciabattoni G, van Gijn J, Nieuwenhuis HK, De Groot PG, Sixma JJ, Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke. 1993;24: 219-223.
18. Patrono C, Davì G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med. 1992;2:15-22.
19. Roth GJ, Calverley DC. Aspirin, platelets and thrombosis: theory and practice. Blood. 1994;83:885-898.
20. Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation. 1993;87: 1873-1879.
21. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart discase. N Engl J Med. 1992;327:175-181.
22. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
23. Dyken ML, Barnett HJM, Easton D, Fields WS, Fuster V, Hachinski V, Norris JW, Sherman DG. Low-dose aspirin and stroke: 'it ain't necessarily so.' Stroke. 1992;23:1395-1399.
24. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 1995;332:238-248.
25. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
26. Helgason CM, Hoff JA, Kondos GT, Brace LD. Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke. 1993;24:1458-1461.
27. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331-2336.
28. Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Stroke. 1994;25:2337-2342.
29. Vejar M, Fragasso G, Hackett D, Lipkin PD, Maseri A, Born GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost. 1990;63:163-168.
30. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, Maclouf J, Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705-1712.
31. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345-1349.
32. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG, and the CATS Group. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
33. ESPS Group. European Stroke Prevention Study. Stroke. 1990;21: 1122-1130.
34. Bousser MG, Eschwege E, Haguenau M, Lefaucconier JM, Thibuet N, Toubul D, Toubul PJ. 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983;14:5-14.
35. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978; 299:53-59.
36. Farrel B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.